GT Biopharma, Inc. Quarterly Common Stock, Shares Authorized from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
GT Biopharma, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q4 2010 to Q3 2024.
  • GT Biopharma, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 250M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 250M 0 0% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 250M 0 0% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 250M 0 0% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 250M 0 0% Dec 31, 2023 10-Q 2024-11-14
Q3 2023 250M 0 0% Sep 30, 2023 10-Q 2023-11-01
Q2 2023 250M -500M -66.7% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 250M -500M -66.7% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 250M 0 0% Dec 31, 2022 10-K 2024-03-26
Q3 2022 250M -1.75B -87.5% Sep 30, 2022 10-Q 2022-10-31
Q2 2022 750M -1.25B -62.5% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 750M -1.25B -62.5% Mar 31, 2022 10-Q 2022-05-16
Q4 2021 250M -500M -66.7% Dec 31, 2021 10-K 2023-03-30
Q3 2021 2B +1.25B +167% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 2B +1.25B +167% Jun 30, 2021 10-Q/A 2021-12-29
Q1 2021 2B +1.25B +167% Mar 31, 2021 10-Q 2021-05-17
Q4 2020 750M -1.25B -62.5% Dec 31, 2020 10-K 2022-03-28
Q3 2020 750M 0 0% Sep 30, 2020 10-Q 2020-11-13
Q2 2020 750M 0 0% Jun 30, 2020 10-Q/A 2020-08-18
Q1 2020 750M 0 0% Mar 31, 2020 10-Q 2020-05-15
Q4 2019 2B +1.25B +167% Dec 31, 2019 10-K 2021-04-16
Q3 2019 750M 0 0% Sep 30, 2019 10-Q 2019-11-14
Q2 2019 750M 0 0% Jun 30, 2019 10-Q 2019-08-14
Q1 2019 750M Mar 31, 2019 10-Q 2019-05-15
Q4 2018 750M 0 0% Dec 31, 2018 10-K 2020-03-27
Q3 2018 750M 0 0% Sep 30, 2018 10-Q 2018-11-14
Q2 2018 750M 0 0% Jun 30, 2018 10-Q 2018-08-14
Q4 2017 750M 0 0% Dec 31, 2017 10-K 2019-03-29
Q3 2017 750M +600M +400% Sep 30, 2017 10-Q 2017-11-14
Q2 2017 750M +600M +400% Jun 30, 2017 10-Q 2017-08-11
Q1 2017 150M -450M -75% Mar 31, 2017 10-Q 2017-04-28
Q4 2016 750M +600M +400% Dec 31, 2016 10-K 2018-03-01
Q3 2016 150M -450M -75% Sep 30, 2016 10-Q/A 2018-02-28
Q2 2016 150M -450M -75% Jun 30, 2016 10-Q/A 2018-02-28
Q1 2016 600M 0 0% Mar 31, 2016 10-Q/A 2018-02-28
Q4 2015 150M +148M +6150% Dec 31, 2015 10-K/A 2018-02-28
Q3 2015 600M 0 0% Sep 30, 2015 10-Q 2015-11-13
Q2 2015 600M 0 0% Jun 30, 2015 10-Q 2015-08-14
Q1 2015 600M 0 0% Mar 31, 2015 10-Q 2015-05-14
Q4 2014 2.4M -598M -99.6% Dec 31, 2014 10-K/A 2018-02-28
Q3 2014 600M 0 0% Sep 30, 2014 10-Q 2015-01-08
Q2 2014 600M 0 0% Jun 30, 2014 10-Q 2015-01-08
Q1 2014 600M 0 0% Mar 31, 2014 10-Q 2015-01-08
Q4 2013 600M 0 0% Dec 31, 2013 10-K 2015-03-31
Q3 2013 600M 0 0% Sep 30, 2013 10-Q 2014-12-17
Q2 2013 600M 0 0% Jun 30, 2013 10-Q 2014-12-12
Q1 2013 600M 0 0% Mar 31, 2013 10-Q 2014-12-10
Q4 2012 600M 0 0% Dec 31, 2012 10-K 2015-01-08
Q3 2012 600M 0 0% Sep 30, 2012 10-Q 2012-11-21
Q2 2012 600M 0 0% Jun 30, 2012 10-Q/A 2012-09-13
Q1 2012 600M Mar 31, 2012 10-Q 2012-05-21
Q4 2011 600M 0 0% Dec 31, 2011 10-K 2014-11-18
Q3 2011 600M Sep 30, 2011 10-Q 2011-11-21
Q2 2011 600M Jun 30, 2011 10-Q/A 2011-09-12
Q4 2010 600M Dec 31, 2010 10-K 2012-04-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.